In a new study, the majority of individuals treated as children for Hodgkin lymphoma who are now in their 30s, showed signs of being an average of 7.7 years older biologically than their peers and placing them at risk for ...
Dec 12, 2022
0
5
Copanlisib plus rituximab (C+R) reduces disease progression or death in patients with relapsed indolent non-Hodgkin lymphoma (iNHL), according to a study presented during Week 1 of the annual meeting of the American Association ...
Apr 14, 2021
0
2
Results of the phase III Inter-B-NHL-ritux 2010 clinical trial reported today in the New England Journal of Medicine show 95 percent three-year survival for pediatric patients with advanced B-cell non-Hodgkin lymphoma treated ...
Jun 4, 2020
0
0
A Stanford Medicine-led, international study of hundreds of samples from patients with Hodgkin lymphoma has shown that levels of tumor DNA circulating in their blood can identify who is responding well to treatment and others ...
Dec 11, 2023
0
38
